Journal
ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION
Volume 98, Issue 2, Pages F122-F126Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/archdischild-2011-301314
Keywords
-
Categories
Funding
- Royal Hobart Hospital Research Foundation [11-382, 12-028]
- National Health and Medical Research Council, Australia [1005345]
Ask authors/readers for more resources
Objective To evaluate the applicability and potential effectiveness of a technique of minimally-invasive surfactant therapy (MIST) in preterm infants on continuous positive airway pressure (CPAP). Methods An open feasibility study of MIST was conducted at two sites. Infants were eligible for MIST if needing CPAP pressure >= 7 cm H2O and FiO(2) >= 0.3 (25-28 weeks gestation, n=38) or >= 0.35 (29-32 weeks, n=23). Without premedication, a narrow-bore catheter was inserted through the vocal cords under direct vision. Surfactant (100 or 200 mg/kg Curosurf) was then instilled, followed by reinstitution of CPAP. Outcomes were compared between surfactant-treated infants and historical controls achieving the same CPAP and FiO(2) thresholds. Results Surfactant was successfully administered via MIST in all cases, with a rapid and sustained reduction in FiO(2) thereafter. For infants at 25-28 weeks gestation, need for intubation <72 h was diminished after MIST compared with controls (32% vs 68%; OR 0.21, 95% CI 0.083 to 0.55), with a similar trend at 29-32 weeks (22% vs 45%; OR 0.34, 95% CI 0.11 to 1.1). Duration of ventilation and incidence of bronchopulmonary dysplasia were similar, but infants receiving MIST had a shorter duration of oxygen therapy. Conclusion Surfactant delivery via a narrow-bore tracheal catheter is feasible and potentially effective, and deserves further investigation in clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available